Rubicon targets Europe for "smallest" embolic filter:
This article was originally published in Clinica
Executive Summary
Rubicon Medical plans to begin clinical studies by the first quarter of 2003 to support a European CE-marking application to use its Rubicon embolic filter in patients with saphenous vein grafts, whereby vessel blockages have reappeared following heart bypass. The device, which is claimed to be smaller and easier to insert into blood vessels than rival devices, targets a potential $1bn worldwide market, says Rubicon. The Salt Lake City, Utah firm will also seek US FDA approval for the device following completion of the European studies.